Form 4: Bioventus Director Susan Stalnecker Equity Update

Director Susan Stalnecker acquired 32,282 shares of Bioventus Class A Common Stock via RSU vesting and was granted 25,146 new RSUs.

Summary

• Director Susan M. Stalnecker acquired 32,282 shares of Class A Common Stock on June 2, 2026, through the vesting of Restricted Stock Units (RSUs).
• Following the transaction, the director's total beneficial ownership increased to 138,239 shares.
• On June 3, 2026, the director was granted an additional 25,146 RSUs.
• The new RSUs are scheduled to vest on the earlier of the day before the next Annual Meeting of Stockholders or the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation and equity ownership.

Positives

• Director maintains a significant equity stake of 138,239 shares, aligning interests with shareholders.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Vesting of the new 25,146 RSUs is contingent upon the director's continued service on the Board of Directors.

Future Outlook

The director holds 25,146 unvested RSUs which will vest on the earlier of the day before the next Annual Meeting of Stockholders or the first anniversary of the grant date, provided service continues.

Industry Context

StockSavvy.ai notes that this filing represents routine equity compensation for board members, which is standard practice for publicly traded medical device companies to ensure director retention and alignment with long-term corporate performance.

Comparison to Industry Standards

• The use of RSU-based compensation for non-employee directors is consistent with standard corporate governance practices in the healthcare and medical technology sectors.
• The vesting schedule tied to annual meetings is a common mechanism used by companies like Zimmer Biomet or Stryker to ensure board continuity.

Stakeholder Impact

• Shareholders may view the director's increased equity position as a positive signal of confidence in the company's long-term prospects.

Next Steps

• Vesting of 25,146 RSUs on the earlier of the day before the next Annual Meeting of Stockholders or June 3, 2027.

Key Dates

Keywords

Bioventus, BVS, Insider Trading, Form 4, Equity Compensation, Director Ownership